-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Peritoneal Cancer Drug Details: Surufatinib (Sulanda) is a potential...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Afatinib Dimaleate in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Afatinib Dimaleate in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Afatinib Dimaleate in Lymphoma Drug Details: Afatinib dimaleate (Giotrif, Gilotrif, Xovoltib)...
-
Sector Analysis
ESG State of Play and Telco Approaches
ESG State of Play and Telco Approaches Report Overview Major tech and telecom companies have a stated commitment to ESG, but their goals, delivery, and reporting can vary substantially. TMT companies are among the key players in the race to net zero. They are not only reducing their carbon footprint, but also enabling others to decarbonize by offering solutions for resource optimization, productivity enhancement, and innovation support. Many telecom operators are publishing sustainability reports which have substantial detail on areas...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Hepatocellular Carcinoma Drug Details: Palbociclib (Ibrance, Agatha) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Thymic Carcinoma Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-441566 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-441566 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAR-441566 in Rheumatoid Arthritis Drug Details: SAR-441566 is under development for the...
-
Thematic Analysis
Mobile Gaming – Thematic Intelligence
Mobile Gaming Thematic Intelligence Report Overview The mobile gaming market is already bigger than the console and PC gaming markets combined. The growing maturity of streaming (supported by 5G), cloud gaming, and mobile esports, combined with the fact that mobile platforms are close to technological parity with PCs and consoles, means most gamers will embrace mobile gaming in the next few years. The mobile gaming thematic intelligence report provides an overview of the mobile gaming theme and identifies the key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Sicca Syndrome (Sjogren) Drug Details: Acloproxalap (ADX-629) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Mantle Cell Lymphoma Drug Details: Sovleplenib (HMPL-523) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Follicular Lymphoma Drug Details: Sovleplenib (HMPL-523) is under development for...